key: cord-1008660-gs4n6156
authors: Pooladanda, Venkatesh; Thatikonda, Sowjanya; Priya Muvvala, Sai; Devabattula, Geetanjali; Godugu, Chandraiah
title: BRD4 targeting nanotherapy prevents lipopolysaccharide induced acute respiratory distress syndrome
date: 2021-03-27
journal: Int J Pharm
DOI: 10.1016/j.ijpharm.2021.120536
sha: 49cbd1d040ce29186a0c583aff826e0e8f38076d
doc_id: 1008660
cord_uid: gs4n6156

Acute respiratory distress syndrome (ARDS) is a life threatening respiratory disease associated with pulmonary edema, alveolar dysfunction, hypoxia, and inflammatory cell accumulation. The most contagious form of COVID-19 associated with ARDS caused by SARS-CoV-2. SARS-CoV-2 majorly produces the cytokine storm and severe lung inflammation and ultimately leads to respiratory failure. ARDS is a complex disease and there is no proper therapeutics for effective therapy. Still, there is a huge scope to identify novel targets to combat respiratory illness. In the current study, we have identified the epigenetic regulating protein BRD4 and developed siRNA based nanomedicine to treat the ARDS. The liposomes were prepared by thin-film hydration method, where BRD4 siRNA complexed with cationic lipid and exhibited 96.24 ± 18.01 nm size and stable even in the presence of RNase. BRD4 siRNA lipoplexes (BRD4-siRNA-LP) inhibited inflammatory cells in lungs and suppressed the lipopolysaccharide (LPS) induced the neutrophil infiltration and mast cell accumulation. Also, BRD4 siRNA based nanomedicine significantly reduced the LPS induced cytokine storm followed by inflammatory signaling pathways. Interestingly, BRD4-siRNA-LP suppressed the LPS-induced p65 and STAT3 nuclear translocation and ameliorated the lung inflammation. Thus, BRD4-siRNA-LP could be a plausible therapeutic option for treating ARDS and might be useful for combating the COVID-19 associated respiratory illness.

Acute respiratory distress syndrome (ARDS) is the pathological condition in critically ill patients associated with pulmonary infiltration and emphysema. ARDS is caused by various etiological factors such as inhalation of toxicants, trauma, adverse drug reactions, drug overdosage, sepsis, and pancreatitis that accounts for 35-46% mortality (Bellani et al., 2016; Diamond et al., 2020) . Recently, the Coronavirus Disease 2019 (COVID-19) represents respiratory illness from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, and became a potential pandemic with more than 38,042,467 sufferers and around 1,085,373 deaths all over the world (Worldometer, 2020) . ARDS is one of the main complications in COVID-19 patients that causes diffuse alveolar damage in the lungs in 42% of patients and 61-81% of that requiring intensive care unit (ICU) support. The induced ARDS is showing wreaking havoc in countries such as the USA, Brazil, India, Russia, UK, Spain, and Italy while ARDS patients have been sustaining in ICU under the ventilation. This virus-associated severe ARDS has a poor prognosis with no proper treatment and various researchers are working on repurposing drugs for symptomatic relief (Möhlenkamp and Thiele, 2020) . LPS (Lipopolysaccharide) is a bacterial endotoxin present on the outer membrane of gram-negative bacteria, an agonist for Toll-like receptor 4 (TLR-4) that mimics the sepsis induced ARDS both in vitro and in vivo (Pu and Wang, 2014) . LPS stimulates macrophages, mast cells, and neutrophils and produces pneumonia-related severe respiratory distress syndrome ultimately causing respiratory failure (Xu and Shi, 2012) . Macrophages are large phagocytic cells found in tissues and blood and mainly appear predominantly in inflammatory conditions (Fujiwara and Kobayashi, 2005) . Additionally, LPS induces oxidative stress and further induce pulmonary edema and impairs pulmonary endothelial barrier function, which is the characteristic phenomenon of the severe acute respiratory syndrome (Grinnell et al., 2012) . LPS stimulation enhances the proinflammatory cytokine levels by activating the p65 nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) , Protein kinase B (Akt), mitogen-activated protein kinase (MAPK) signaling pathways which are involved in the perpetuation of the inflammatory responses (Alvira, 2014; Guha and Mackman, 2002; Selvaraj et al., 2015) . LPS stimulation also triggers the translocation of transcription factors p65 NF-κB as well as Signal transducer and activator of transcription 3 (STAT3) from cytoplasm to nucleus, thus initiates the transcription of various proinflammatory genes responsible for cytokine storm (Bagaev et al., 2019) . LPS induced inflammation may mimic the sepsis condition and most of the aspects of COVID-19 associated ARDS, although, it does not completely resemble the SARS-CoV-2 induced ARDS, but the deleterious effects associated can be resembled.The bromodomain (BD) is a structural motif within the proteins family that recognizes the acetylated lysine residues and employed in epigenetic modification through histone regulation as "readers" that orchestrate gene transcription (Miller et al., 2016) . The bromodomain and extra terminal domain (BET) proteins are identified as BRD2, BRD3, BRD4, and testis-specific BRDt, among all, BRD4 plays an important role in inflammation and cancer (Klein, 2018) . Generally, BET proteins have two conserved BDs, they involve recognizing acetylated histones and act as scaffolds to recruit transcriptional co-activators to promoters and super-enhancers, thereby drive gene transcription (Cochran et al., 2019) . In inflammation, BDs identify the acetylated lysines on non-histone proteins such as RelA known as p65 NF-κB, which plays an important role in this condition (Hajmirza et al., 2018) . BRD4 inhibitors were used in alleviating various diseases in the lung inflammation, cancer etc., and most of these are under clinical trials (Duan et al., 2018) . However, BRD4 mechanism and its role in ARDS condition are not clear. Hence, in the current study, we evaluated the role of BRD4 in mediating inflammatory responses. Furthermore, BRD4 was attenuated with siRNA to abrogate its function and the effect was investigated.

Lipoplexes are the cationic liposomes, classically used as nonviral synthetic lipid carriers of DNA. These lipoplexes enhance the therapeutic bioavailability of drugs or genes through enhanced permeability and retention (EPR) effect (Deshpande et al., 2013) . These lipoplexes are widely used in gene delivery including Small interfering RNA (siRNA), micro RNA (miRNA), and short hairpin RNA (shRNA) (Shim et al., 2013) . siRNAs are artificially synthesized 20-30 nucleotides long double-stranded RNA molecules, which are routinely used in molecular biology for transient silencing of a gene of interest. They elicit RNA interference (RNAi) response upon binding to their target transcript based on the sequence complementarity and siRNA therapeutics are employed as an alternative to traditional drugs for the management of various diseases (Dana et al., 2017) . However, safe and effective siRNA delivery to the affected site is hampered by poor stability, highly hydrophilic nature, and low cellular uptake of siRNA (Wang et al., 2010) . siRNA is negative in charge and forms the electrostatic interactions with cationic lipid DOTAP and forms lipoplexes. Further, these siRNA lipoplexes were uptaken by cells through endocytosis mediated pathway (Alshehri et al., 2018; Schroeder et al., 2010) . Mainly, in lung diseases, siRNA lipoplexes are administered to lungs through inhalation or intravenous route, as this route of administration of siRNA lipoplexes have the advantage of being less invasive (Qiu et al., 2016) . In the current study, for delivering the BRD4 siRNA into the lungs, we have prepared the nanosized cationic lipoplexes for the downregulation of corresponding BRD4 mRNA and further investigated the mechanistic insights of BRD4 inhibition in LPS induced ARDS conditions both in vitro and in vivo.

BRD4 siRNA was procured from Santa Cruz Biotechnology, USA. 1,2-dioleoyl-3-trimethyl ammonium propane (DOTAP) (chloride salt) was purchased from Avanti polar lipids, USA.

LPS from Escherichia coli (055: B5), PFI-1, Cholesterol (Chol), Trizma Base, SDS, acrylamide, DCFDA, and FITC were procured from Sigma Aldrich, USA. Agarose was procured from Merk, USA. SYBR Green I was purchased from Thermo Fisher Scientific, USA. The primary and secondary antibodies were purchased from Cell Signaling Technologies, USA and Santa Cruz Biotechnology, USA, respectively. All the chemicals which are used in this study are analytically pure and molecular grade.

BRD4 siRNA lipoplexes (BRD4-siRNA-LP) were prepared using the previously reported methods by dissolving DOTAP and Chol in chloroform in a 1:1 molar ratio (Pandi et al., 2018) . Thin-film was formed by rotary evaporation, which is hydrated with Diethylpyrocarbonate (DEPC) treated water at 37 °C to form multilamellar vesicles (MLV). Further, MLV containing liposomes were subjected to probe sonication to form nanosized liposomes. The stable complex of siRNA lipoplexes was prepared by mixing the siRNA/lipid (N/P) molar ratio by incubating at 37 °C for 30 min. Whereas, blank lipoplexes (Blank-LP) were prepared similar to siRNA lipoplexes without BRD4 siRNA.

siRNA easily undergoes ribonucleolytic degradation, while the lipoplex form enhances the stability, agarose gel electrophoresis is used to study the formation of BRD4-siRNA-LP (Patil et al., 2011) . In this study, to test the stability of BRD4 siRNA in lipoplexes, they were prepared and loaded on to the gel by mixing in 1X loading dye. Plain BRD4 siRNA was employed for comparison. 3% agarose gel was prepared by adding ethidium bromide and electrophoresis was performed under the conditions of 60 mA for 35 min. The bands were visualized by the Chemidoc system at 365 nm.

Lipoplexes particle size and size distribution were measured by Zetasizer Nano-ZS in DTS0012 plastic cells (Malvern instrument Ltd. UK). The entrapment of siRNA in cationic lipoplexes was determined as described earlier (Jain et al., 2017) , where the standard curve of siRNA was plotted by using the nanodrop spectrophotometer and calculated the unknown concentration of siRNA in the supernatant after centrifugation of lipoplexes at 16000 rpm for 10 min from the standard curve followed by measured the bounded and unbounded siRNA concentration from the values. The percentage of entrapment efficiency was calculated using the following formula. 

In in vivo, mice were divided into 7 groups (n=8) including normal control (NC), LPS control, BRD4-siRNA-LP control, blank lipoplexes (Blank-LP), BRD4-siRNA-LP pretreatment (Pre) and concurrent (Con) treatment and PFI-1 (5 mg/kg) groups. In the pretreatment group, animals were administered with BRD4-siRNA-LP 5 days before LPS stimulation, where the concurrent group animals received BRD4-siRNA-LP along with LPS.

Here, mice were treated with 500 nM siRNA. Whereas, NC group animals received only PBS. Here, the lipoplexes, PFI-1, LPS, and PBS were administered by the oropharyngeal route. Animals were sacrificed by isoflurane overexposure after 12 h of LPS poststimulation. The collected lung tissues were stored in -80 ο C.

Net body weight changes measured by taking the values before and after LPS stimulation and lung weight index was calculated as described earlier (Pooladanda et al., 2019) .

After sacrifice, lungs were lavaged with ice-cold PBS for 3 times, bronchoalveolar samples were collected, pooled, and centrifuged for 10 min at 300 g. Cell pellets obtained were suspended in PBS (1ml) and subjected to differential cell counter ADVIA 2120i hematology system (Siemens, Germany).

IL-1β, IL-6, IL-17A, IL-22, and TNF-α levels in lung tissue lysates were analyzed by ELISA according to the manufacturer instructions (Thermo Fisher Scientific, USA).

Specific Antigen-antibody interaction, location, and distribution can be determined by immunofluorescence by using the flourochrome detection system. In this method, cells were fixed in 4% paraformaldehyde and permeabilized with 0.1% Triton X-100, whereas 5 µm sections of lung tissues were deparaffinized, rehydrated and then antigen was unmasked by treating with proteinase k for 15 min. Non-specific binding portions were eliminated by 3%

BSA blocking solution and incubated with primary antibodies (1:100 dilutions) overnight at 4℃ and later suitable dye conjugated secondary antibodies were added and incubated. Cells and tissue sections were washed thrice with immune wash buffer and probed with rhodamine or fluorescein isothiocyanate (FITC) (Sigma-Aldrich, USA) conjugated anti-mouse or antirabbit (1:200 dilutions) for 1 hour and nuclei was stained with DAPI stain (Sigma-Aldrich, USA), after mounting slides with Fluoreshield TM histology medium, visualized under the confocal microscope.

Lung tissues were moulded in paraffin wax, and tissue sectioning was performed by microtome (Leica, Germany). Poly-L-Lysine coated slides were used to collect the tissue sections. For histological evaluation, tissue sections were stained with H&E and visualized under the microscope at ×400 magnification Histopathological score was determined as described earlier (Pooladanda et al., 2021) .

Tissue sections were stained with toluidine blue (TB) and evaluated the mast cell infiltration.

Images were captured at × 400 magnifications by bright-field microscope (Olympus CX21i, Japan). Mast cells were counted and represented as described earlier (Pooladanda et al., 2019) .

Protein lysate was extracted from cells as well as from lung tissues as described earlier . Bicinchonic acid (BCA) calorimetric assay kit (Sigma-Aldrich, USA) was used for the estimation of protein concentration. Protein samples were loaded and subjected to Sodium dodecyl sulfate-Polyacrylamide gel electrophoresis (SDS-PAGE).

Proteins were electrotransferred according to their molecular weight onto nylon membrane (Sigma-Aldrich, USA); later proteins were visualized based on their molecular weights by placing membranes in Ponceau S stain. Non-specific binding of antibodies was avoided by a 3% blocking solution and incubated overnight with primary antibody at 4 ο C, later secondary antibody was added and detected by using enhanced chemiluminescence (ECL) substrate (Bio-Rad, USA). Blots were developed by the Chemidoc imaging system (Vilber Fusion Fx, France). Images were analyzed by ImageJ software, NIH, USA. Protein normalization was done by β-Actin and their respective total proteins.

All the results were analyzed by Graphpad Prism, USA (version 6.01) software, where n represents the number of replicates. One-way analysis of variance (ANOVA) was applied along with the Bonferroni post hoc test for statistical analysis. Here, p< 0.05 was considered statistically significant.

Lipoplexes were prepared by thin-film hydration method. The particle size, polydispersity index (PDI), and charge were determined by Zetameter. Where, the particle size of Blank-LP and BRD4-siRNA-LP were found to be 95.25 ± 9.49 ( Figure 1A ) and 96.24 ± 18.01 nm ( Figure 1B) , respectively, whereas the PDI was found to be 0.24 ± 0.02 and 0.25 ± 0.03, respectively. The Blank-LP and BRD4-siRNA-LP exhibited charge of 32.78 ± 2.71 ( Figure   1C ) and 30.25 ± 2.01 mV (Figure 1D ), respectively. Stable complexes are a prerequisite to deliver the siRNA and to overcome serum instability or a high clearance rate in vivo (Pal .98%, and also shows enhanced stability of BRD4-siRNA-LP, whereas plain BRD4 siRNA was easily degraded in presence of RNase ( Figure 1F) . Collectively, the prepared BRD4-siRNA-LP were nanosized, exhibited uniform size with positive charge and formed stable complexes.

Western blot results revealed that BRD4-siRNA-LP significantly suppressed LPS induced BRD4 expression in lung tissues, similar kind of decreased expression was also observed with BRD4 inhibitor PFI-1 (Figure 2A and Figure S1A ). The oropharyngeal administration of LPS in mice led to a decrease in net body weight (Figure 2B) , and significantly increased the lung weight index (Figure 2C) , which further contributes to pulmonary edema.

Interestingly showed a prominent reduction in nitrite levels, whereas the BRD4-siRNA-LP alone group exhibited no significant changes in healthy animals ( Figure 3A ). Nitrosative and oxidative stress were neutralized by anti-oxidant defensive switches that include superoxide dismutase (SOD) and glutathione (GSH) (Kurutas, 2015) . In our study, we have observed that SOD ( Figure 3B ) levels were significantly increased by BRD4-siRNA-LP treated animals as compared to LPS control group animals, however, there were no changes observed in PFI-1 treatment group. Apparently, we observed that both BRD4-siRNA-LP and PFI-1 moderately enhanced the GSH levels but not to a significant extent (Figure 3C) ,

LPS induction increased IL-1β (Figure 3D ), IL-6 ( Figure 3E) , IL-17A (Figure 3F ), IL-22 (Figure 3G) , and TNF-α ( Figure 3H ) levels, whereas these cytokines were significantly reduced by BRD4-siRNA-LP concurrent group, and showed superior effect compared to pre-treatment with siRNA lipoplexes and PFI-1. Here, PFI-1 slightly reduced IL-6 and IL-22 but non-significant. BRD4-siRNA-LP alone group did not induce the proinflammatory cytokines and the levels were in the normal range. Furthermore, we evaluated the expression of iNOS, TNF-α, and IL-6 by immunoblotting. Figure 3I and Figure S2A -C infers that targeting BRD4 with lipoplexes as well as PFI-1 significantly suppressed the LPS induced iNOS, IL-6, and TNF-α expression, whereas BRD4-siRNA-LP alone group did not alter the expression of these inflammatory proteins. Collectively, targeted inhibition of BRD4 and inhibiting the expression by BRD4-siRNA-LP hampers the cytokine storm, and we speculate that it has beneficial effects in protecting the lungs from COVID-19 associated respiratory failure.

Excessive inflammatory cytokines promote neutrophil infiltration and mast cell accumulation, which is responsible for respiratory illness (Moldoveanu et al., 2008) . and mast cell accumulation was observed. Moreover, we found that when compared to the BRD4-siRNA-LP pre-treatment group, concurrent group exhibited a more significant reduction in contrast to the LPS challenged group. Furthermore, epithelial barrier dysfunction was indistinguishable in BRD4-siRNA-LP alone group with normal pulmonary architecture.

However, PFI-1 treatment exhibited similar results, but in comparison, BRD4-siRNA-LP exhibited better effects. Thus, BRD4 inhibition mitigated the LPS induced alveolar disruption and further protected against pulmonary edema and alveolar damage.

The next goal of this study was to evaluate the molecular mechanism by BRD4-siRNA-LP in lung inflammation. The oxidative stress plays a crucial role in exacerbating ARDS and further involve in cytokine mediated inflammation (Kellner et al., 2017) . To examine this effect; the in vitro experimentation was performed in RAW 264.7 cells. Initially, BRD4 knockdown studies were performed by treating the cells with different concentrations of BRD4-siRNA-LP at 1, 2.5, 5, and 10 nM and incubated for 48h, then stimulated with LPS for 30 min. Then we quantified the BRD4 protein expression and observed a significant knockdown of BRD4 expression at 10 nM ( Figure 5A and Figure S3A ) and further studies were executed with this concentration. LPS induced oxidative damage in macrophages at 1 μg/ml, while in BRD4-siRNA-LP transfection at 10 nM concentration resulted in significant decreased the ROS levels, and no distinguishable changes occured in the BRD4-siRNA-LP alone treatment (Figure 5B & C) . We next explored whether BRD4 has a direct impact on Akt and MAPK signaling using a loss of function of BRD4 by BRD4-siRNA-LP as it plays a crucial role in both inflammation and aggravate respiratory illness and LPS mimics this condition. It was found that LPS induced Akt (at Thr308 and Ser473), p38, p44/42, SAPK/JNK phosphorylation, where activation was also found with Blank-LP, and knock down of BRD4 significantly inhibited protein expression (Figure 5D and Figure S3B-C) .

These results show that BRD4 is a selective target for oxidative stress and inflammation in ARDS.

Previous reports suggest that the anti-inflammatory potential of BET bromodomain binding to acetylated histones disrupt the LPS-induced expression of inflammatory cytokines and the formation of the chromatin complexes (Nicodeme et al., 2010) . Consistently we observed that LPS enhanced the BRD4 mediated inflammation in ARDS mouse model, and was involved in the upregulation of Akt (Thr308 and Ser473), mTOR and GSK-3β phosphorylation ( Figure 6A and Figure S4A -E). However, targeting BRD4 with BRD4-siRNA-LP and PFI-1 suppressed these inflammatory genes expression. Additionally, BRD4-siRNA-LP and PFI-1 inhibited the LPS induced phosphorylation of SAPK/JNK, p44/42, and p38 ( Figure 6B and Figure S4F-H) . Here, we observed that BRD4-siRNA-LP showed superior activity over PFI-1 treatment, and BRD4-siRNA-LP alone did not promote the activation of inflammatory cascade in the mouse upon oropharyngeal administration of LPS. Thus, targeting BRD4

inhibits the Akt/mTOR/MAPK signaling and ameliorates the LPS induced ARDS. P

TLR-4 agonist LPS induces the inflammation by stimulating the p65 NF-κB signaling and causes severe respiratory illness. In our study, we found that LPS induced the phosphorylation of IKK-α/β, IκB-α, p65 NF-κB, and STAT3, which were significantly inhibited by BRD4-siRNA-LP ( Figure 7A and Figure S5A-D) . Additionally, we observed that LPS induced nuclear p65 NF-κB and STAT3 protein expression was significantly ameliorated by BRD4-siRNA-LP ( Figure 7B and Figure S5E & F) . The transcriptional factors, p65 and STAT3, did not exhibit activity when they reside in the cytoplasm. However, these transcriptional factors were phosphorylated in the presence of inflammatory stimuli, and then enter into the nucleus, where they induced the expression of a wide variety of inflammatory genes, which are responsible for the respiratory collapse. Confocal microscopy results infer that LPS induced nuclear translocation of p65 and STAT3 is significantly downregulated by BRD4-siRNA-LP ( Figure 7C) . Collectively, BRD4-siRNA-LP ameliorated the LPS induced ARDS by suppressing p65 and STAT3 crosstalk.

TLR-4 agonist LPS activated TRAF-6 mediated p65 signaling and actively participated in inflammatory signaling cascade observed in C57/BL6 mice. Targeting BRD4 with novel drug delivery system BRD4-siRNA-LP and small-molecule inhibitor PFI-1 inhibited the phosphorylation of IKK-α/β, IκB-α, p65 and STAT3 along with TRAF6 expression.

However, the Blank-LP group did not reverse the LPS mediated changes and BRD4-siRNA-LP alone did not produce any inflammation and remained similar as NC (Figure 8A and Figure S6A -E). Similar to in vitro results, here, we observed that BRD4-siRNA-LP suppressed LPS induced nuclear p65 NF-κB and STAT3 expression ( Figure 8B and Figure   S6F & G). Additionally, BRD4-siRNA-LP inhibited the nuclear translocation of p65 and STAT3 in LPS challenged mice ( Figure 8C) . We also noticed that the small molecule inhibitor PFI-1 significantly inhibited the expression of p65 NF-κB and STAT3. Collectively, BRD4 is a novel target, which is upregulated by inflammatory stimulus and induces the nuclear translocation of p65 and STAT3. Thus targeting it by novel lipoplex delivery system will be an useful aid for treating COVID-19 associated ARDS.

Acute respiratory distress syndrome (ARDS) is a severe form of lung injury in critically ill patients. It is caused by higher levels of free reactive oxygen species and nitrogen species and is responsible for the activation of various inflammatory mediators leading to hypoxemic pulmonary edema, and the need for mechanical ventilation (Kellner et al., 2017; Ricciardolo et al., 2006) . ARDS most often occur with severe trauma, pneumonia, aspiration of gastric contents, bacterial sepsis or with viral infections from human coronaviruses such as severe acute respiratory syndrome coronavirus (SARS-CoV), middle east respiratory syndrome coronavirus (MERS-CoV) and a recent outbreak from COVID-19 associated novel coronavirus SARS-CoV-2 infections, which can progress to refractory pulmonary failure and ultimately increases mortality rates (Petrosillo et al., 2020; Naeem, 2013) . Despite its high incidence, there are no specific approved drugs to treat this condition. Supportive therapies such as restrictive fluid therapy, extracorporeal membrane oxygenation (ECMO) and prone positioning are some of the management strategies. These interventions improve the ARDS outcome but do not reduce the lung injury burden (Peck and Hibbert, 2019) . In ARDS conditions, persistent inflammatory responses are observed as the air spaces are predominantly filled with infiltration of macrophages and neutrophills (Baudouin, 2006) . In an attempt to improve the outcome, corticosteroid treatment was analyzed in ARDS patients, but their efficacy and beneficial effects in patients are divergent and controversial (Khilnani and Hadda, 2011) . Unfortunately, sometimes ventilation also exacerbates ARDS by perpetuating local and systemic inflammation that further increases the mortality rates (Hough, 2014; Joseph et al., 2018) . Recently, in COVID-19 induced ARDS cases, Aviptadil, a synthetic form of human vasoactive intestinal polypeptide (VIP) and Ruxolitinib, a selective Janus kinase (JAK) inhibitor are being investigated for ARDS treatment, which are under clinical trials (NCT04311697) (NCT04359290). However, there is still a huge scope to find new therapeutic targets and new drugs for this devastating ARDS condition.

The structural motif, BRD4 is a member of the BET family that recognizes acetyllysine residues in both histone and non-histone proteins that orchestrate gene transcription by functioning as "readers". BRD4 is implicated in several lung disease conditions such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis (Tian et al., 2016) , lung cancer (Gao et al., 2018) and, asthma (Sanders and Thannickal, 2018) . In the present study, protein E binds with BRD2 and BRD4, thus, targeting BRD4 may inhibit the viral fusion into host cells as well as respiratory illness (Gordon et al., 2020) . These findings raise an intriguing possibility that BRD4 might be involved in ARDS conditions. Consistent with this expectation, after LPS oropharyngeal instillation, the net body weights were found to be decreased, whereas increased lung weight index was observed. Interestingly, BRD-siRNA-LP treated groups, there were no major physiological alterations. Moreover, BRD4-siRNA-LP suppressed the LPS induced total cells, WBC, neutrophils, monocytes, and basophils counts, and protected the epithelial barrier dysfunction. In ARDS patients cytokines such as TNF-α, IL-1β, IL-6, and IL-8 are elevated in BAL fluid and circulating plasma (Han and Mallampalli, 2015) . In COVID-19 associated critically ill patients in Intensive care unit (ICU) wards, higher plasma levels of various inflammatory cytokines including MCP -1, MIP -1A, GSCF, TNF-α, IL -2, IL -7, IL -10, and IP -10 were observed .

This cytokine storm perpetuates inflammatory immune cell infiltration, causes accumulation of protein-rich edema fluid into the alveoli with hypoxemia which is caused due to impairment of gas exchange (Pedersen and Ho, 2020) . Hence, antioxidant therapy might be useful in ameliorating the ARDS condition (Wang et al., 2020) . Here, LPS induced the nitrite levels and reduced the SOD and GSH levels, whereas BRD4-siRNA-LP inhibited nitrosative and oxidative stress by upregulating the antioxidant defensive mechanism. BRD4-siRNA-LP reversed the LPS induced cytokine storm by significantly suppressing pro-inflammatory cytokine levels including IL-1β, IL-6, IL-17A, IL22, and TNF-α. From H & E and Toulidine blue staining, it was observed that BRD4-siRNA-LP suppressed the LPS induced neutrophil and mast cell infiltration and protected the lungs from immune cell-mediated cytokine storm.

Targeting BRD4 suppresses the PI3K-Akt/MAPK/JNK signaling in cancer and inflammatory diseases, and these pathways important in the regulation of inflammatory responses Stratikopoulos et al., 2015; Wang et al., 2018) . In line with this, previous reports suggest that JNK, p38, and PI3K/Akt were involved in severe acute respiratory distress syndrome-coronavirus (SARS-CoV) infected Vero E6 cells, which suggest the possible involvement of inflammation in COVID-19 associated ARDS through this signaling (Mizutani et al., 2005 coactivates the NF-κB transcriptional activity by acetylating p65 also known as RelA (Huang et al., 2009) . Upon IκB-α degradation, p65 moves into the nucleus, and further induces the transcription of various inflammatory genes and evokes the ARDS (Moine et al., 2000) . The accumulating evidence suggest that deletion of BRD4 in macrophages showed constant MAP kinase-interacting serine/threonine-protein kinase 2 (Mknk2) and involved in the activation of eIF4E, which further aided in IκBα mRNA translation, which ultimately suppressed the NF-κB mediated inflammatory signaling and demonstrated that conditional knock out of BRD4 in mice were resistant to the sepsis conditions induced by LPS, which depicts the role of BRD4 in regulating the innate immune response (Bao et al., 2017) . With respect to this paradigm, in our experimentation, we have observed that LPS induced the phosphorylation of IKK-α/β, IκB-α, and p65, whereas this effect was significantly inhibited by BRD4-siRNA-LP. Accumulating evidence suggest that pro-inflammatory cytokine stimulus activates the STAT3 and NF-κB crosstalk through TRAF6 and p65 dependent mechanism (Yoshida et al., 2004) . On the other hand, STAT3 retains the nuclear-bounded p65, thus promotes persistent inflammation (Yu et al., 2009) In addition, targeting BRD4 inhibits the STAT3-dependent MYC expression in cancer, however, it is not yet elucidated in inflammatory condition (Ray et al., 2014) . In our study, we noticed that BRD4 inhibition suppressed the STAT3 phosphorylation. We also observed that BRD4-siRNA-LP significantly inhibited p65 and STAT3 and further reduced the activation of inflammatory proteins expression. This might be therefore a promising novel target with the potentially advantageous delivery systems, which may be considered in treating COVID-19 induced ARDS (Figure 9) .

Collectively, our results infer that BRD4 is a novel target for ARDS irrespective of its origin.

The LPS induced ARDS model may mimic the COVID-19 associated ARDS. Inhibition of BRD4 by BRD4-siRNA-LP might play an important role in treating clinical COVID-19-ARDS patients potentially through anti-inflammatory and anticytokine storm properties by controlling p65 and STAT3 nuclear translocation. Thus, it could be a better therapeutic strategy for treating COVID-19 induced ARDS in this global pandemic.

Authors declare no conflict of interest.

Coperchini, F., Chiovato, L., Croce, L., Magri, F., Rotondi, M., 2020. The Cytokine storm in 

Pathways of cellular internalisation of liposomes delivered siRNA and effects on siRNA engagement with target mRNA and silencing in cancer cells

Nuclear factor-kappa-B signaling in lung development and disease: one pathway, numerous functions

Elevated pre-activation basal level of nuclear NF-κB in native macrophages accelerates LPS-induced translocation of cytosolic NF-κB into the cell nucleus

Brd4 modulates the innate immune response through Mnk2-eIF4E pathwaydependent translational control of IκBα

Manipulation of inflammation in ARDS: achievable goal or distant target?

Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries

Neutrophils and COVID-19: The road so far

Current development of siRNA bioconjugates: From Research to the Clinic

Bromodomains: a new target class for drug development

Macrophages in inflammation

Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression

A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing

Protection against LPS-induced pulmonary edema through the attenuation of protein tyrosine phosphatase-1B oxidation

The phosphatidylinositol 3-Kinase-akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells

BET family protein BRD4: An emerging actor in nfκb signaling in inflammation and cancer

The acute respiratory distress syndrome: from mechanism to translation

Should we ever give steroids to ARDS patients?

BRD4 coactivates transcriptional activation of NF-κB via specific binding to acetylated RelA

Liposphere mediated topical delivery of thymoquinone in the treatment of psoriasis

Strategies to prevent ventilator-associated lung injury in critically Ill patients

ROS signaling in the pathogenesis of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS)

Corticosteroids and ARDS: A review of treatment and prevention evidence

Bromodomain protein inhibition: a novel therapeutic strategy in rheumatic diseases

The importance of antioxidants which play the role in cellular response against oxidative/nitrosative stress: current state

Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer

Covid-19: what treatments are being investigated

A bromodomain-DNA interaction facilitates acetylationdependent bivalent nucleosome recognition by the BET protein BRDT

JNK and PI3k/Akt signaling pathways are required for establishing persistent SARS-CoV infection in Vero E6 cells

Ventilation of COVID-19 patients in intensive care units

NF-kappaB regulatory mechanisms in alveolar macrophages from patients with acute respiratory distress syndrome

Inflammatory mechanisms in the lung

Middle East Respiratory Syndrome (MERS) -An update

Suppression of inflammation by a synthetic histone mimic

Lipoplex-based therapeutics for effective oligonucleotide delivery: a compendious review

Dendrimer as a new potential carrier for topical delivery of siRNA: A comparative study of dendriplex vs. lipoplex for delivery of TNF-α siRNA

Synthesis and efficient siRNA delivery of polyamine-conjugated cationic nucleoside lipids

Recent advances in the understanding and management of ARDS

SARS-CoV-2: a storm is raging

COVID-19, SARS and MERS: are they closely related?

Nimbolide protects against endotoxin-induced acute respiratory distress syndrome by inhibiting TNF-α mediated NF-κB and HDAC-3 nuclear translocation

The current understanding and potential therapeutic options to combat COVID-19

2021. iRGD conjugated nimbolide liposomes protect against endotoxin induced acute respiratory distress syndrome

Toll-like receptor 4 agonist, lipopolysaccharide, increases the expression levels of cytokines and chemokines in human peripheral blood mononuclear cells

Delivery of RNAi therapeutics to the airways-from bench to bedside

Inducible STAT3 NH2 Terminal mono-ubiquitination promotes BRD4 complex formation to regulate apoptosis

Covid-19 cytokine storm in pulmonary tissue: Anatomopathological and immunohistochemical findings

Reactive nitrogen species in the respiratory tract

BETting on Novel Treatments for Asthma: Bromodomain 4 Inhibitors

Lipid-based nanotherapeutics for siRNA delivery

Lipopolysaccharide induced MAP kinase activation in RAW 264.7 cells attenuated by cerium oxide nanoparticles

Application of cationic liposomes for delivery of nucleic acids

Features of Oxidative and Nitrosative Metabolism in Lung Diseases

Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy

Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation

Oxidative Stress Mechanisms in the Pathogenesis of Environmental Lung Diseases. Oxidative Stress in Lung Diseases 103-137

BRD4 mediates NF-κB-dependent epithelial-mesenchymal transition and pulmonary fibrosis via transcriptional elongation

(+)-JQ1 attenuated LPS-induced microglial inflammation via MAPK/NFκB signaling

Delivery of siRNA therapeutics: barriers and carriers

An anti-oxidative therapy for ameliorating cardiac injuries of critically ill COVID-19-infected patients

Emerging Role of Mast Cells and Macrophages in Cardiovascular and Metabolic Diseases

Interleukin 1 activates STAT3/nuclear factor-kappaB cross-talk via a unique TRAF6-and p65-dependent mechanism